A review of insulin pen devices

Postgraduate Medicine

Volumn 122, Issue 3, 2010, Pages 81-88

  McCoy, Emily K ^a   Wright, Bradley M ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Diabetes; Insulin; Insulin pen device; Vial and syringe

Indexed keywords

FLEXPEN; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; NEUTRAL INSULIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING DRUG; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

BEDTIME DOSAGE; DEVICE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELF ADMINISTRATION; DRUG STABILITY; DRUG STORAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN PEN; INTERMETHOD COMPARISON; MICROANGIOPATHY; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PATIENT PREFERENCE; PRESCRIPTION; REVIEW; SYRINGE; EQUIPMENT DESIGN; INSTRUMENTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

DIABETES MELLITUS, TYPE 2; EQUIPMENT DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; SELF ADMINISTRATION; SYRINGES;

EID: 77953114761     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.05.2145     Document Type: Review

References (60)

1. Department of Health and Human Services, Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. General information. http://www.cdc.gov. Accessed March 23, 2010.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-986.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS 33) Group. Lancet. 1998;352(9131):837-853.
4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012.
5. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(suppl 1):S11-S61.
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
7. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26(3):917-932.
8. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-1972.
9. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81-86.
10. Cryer PE, Childs BP. Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum. 2002;15(1):20-27.
11. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(suppl 3):S18-S24.
12. Peyrot M, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes, Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679.
13. Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25(1):36-38.
14. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20(3):292-298.
15. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543-2545.
16. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498-1505.
17. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91(1):1-9.
18. Starkman HS, Gleason RE, Rand LI, Miller DE, Soeldner JS. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann Rheum Dis. 1986;45(2):130-135.
19. Ziegler D, Gries FA, Spüler M, Lessman F. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabetes Med. 1993;10(suppl 2):82S-86S.
20. Spollett G. Insulin devices: addressing barriers to insulin therapy with the ideal pen. Diabetes Educator. 2008;34(6):957-960, 963, 967.
21. Bell DS, Clements RS Jr, Perentesis G, Roddam R, Wagenknecht L. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med. 1991;151(11):2265-2269.
22. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998;79(1):59-62.
23. Rosenstock J. Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging. 2001;18(1):31-44.
24. DeWitt DE, Hirsh IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289(17):2254-2264.
25. Levemir (insulin detemir) [package insert]. Princeton, NJ: Novo Nordisk; August 2009.
26. Novolin N (NPH) [package insert]. Princeton, NJ: Novo Nordisk; June 2009.
27. Humulin N (NPH) [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2007.
28. Lantus (insulin glargine) [package insert]. Bridgewater, NJ: sanofi-aventis; March 2007.
29. Novolog (insulin asparte) [package insert]. Princeton, NJ: Novo Nordisk; October 2009.
30. Humalog (insulin lispro) [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2009.
31. Apidra (insulin glulisine) [package insert]. Bridgewater, NJ: sanofi-aventis; February 2009.
32. Novolin R (regular human insulin) [package insert]. Princeton, NJ: Novo Nordisk; June 2009.
33. Humulin R (regular human insulin) [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2007.
34. Novolog Mix 70/30 (insulin aspart/insulin aspart protamine) [package insert]. Princeton, NJ: Novo Nordisk; August 2009.
35. Humalog 75/25 (insulin lispro/insulin lispro protamine) [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2009.
36. Humalog 50/50 (insulin lispro/insulin lispro protamine) [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2009.
37. Novolin 70/30 (regular human insulin/human insulin isophane) [package insert]. Princeton, NJ: Novo Nordisk; June 2009.
38. Humulin 70/30 (NPH/regular human insulin) [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2007.
39. Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260-265.
40. Kroon L. Overview of insulin delivery pen devices [published online ahead of print August 18, 2009]. J Am Pharm Assoc.
41. Novo Nordisk. Novo Nordisk care. http://www.novonordiskcare.com. Accessed March 22, 2010.
42. Eli Lilly and Company. Insulin pens. http://www.insidehumalog.com. Accessed March 22, 2010.
43. Sanofi-aventis. OptiClik®. http://www.opticlik.com. Accessed March 22, 2010.
44. Owen Mumford. Autopen. http://www.owenmumford.com/en/range/6/autopen.html. Accessed March 22, 2010.
45. Sanofi-aventis. Lantus SoloSTAR® Pen. http://www.lantus.com. Accessed March 22, 2010.
46. Sanofi-aventis. Apidra SoloSTAR® Pen. http://www.apidra.com. Accessed March 22, 2010.
47. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4(2):165-174.
48. Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patientreported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11(8):529-538.
49. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-496.
50. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27(suppl B):S89-S100.
51. Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Invest. 2006;26(7):367-401.
52. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, Lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29(4):650-660.
53. Shaghouli AA, Shah BR. The prescription of insulin pen devices versus syringes for older people with diabetes. Diabetes Technol Ther. 2009;11(7):439-442.
54. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948-962.
55. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-1725.
56. Asakura T, Seino H, Nakano R, et al. A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther. 2009;11(10):657-661.
57. Korytowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, twoperiod cross over trial of preference, efficacy, and safety profiles of a prefilled disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848.
58. Davis EM, Christensen CM, Nystrom KK, Foral PA, Destache C. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65(14):1347-1357.
59. Magnolti MA, Rayfield EJ. An update on insulin injection devices. Insulin. 2007;2(4):173-181.
60. Drugstore. com. Drug prices. http://www.drugstore.com. Accessed March 29, 2010.